Akero Therapeutics, Inc. (AKRO) earnings
AKRO earnings moved a median of +0.09% by the close. Quarterly and annual AKRO reports and results, each read against the price at its own news timestamp. Back to the AKRO overview →
15 measured AKRO earnings events.
Where these AKRO earnings landedvs 15 measured AKRO earnings reactions
| Middle 50% of AKRO earnings reactions | -2.25% to +1.18% |
|---|---|
| Median reaction (to close) | +0.09% |
| Measured reactions | 15 |
Point-in-time · zero look-ahead
Half of the 15 AKRO earnings events with a measured close landed between -2.25% and +1.18%; 53% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Akero Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.08% | +0.09% | |
| Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | +1.41% | +1.41% | |
| Form 10-Q Akero Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +1.41% | +1.41% | |
| Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | +2.90% | +3.57% | |
| Form 10-Q Akero Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +2.90% | +3.57% | |
| Form 10-K Akero Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -4.83% | +0.94% | |
| Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | -2.04% | -0.81% | |
| Form 10-Q Akero Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -2.04% | -0.81% | |
| Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | -2.29% | -2.25% | |
| Form 10-Q Akero Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -2.29% | -2.25% | |
| Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update | Press release | -0.98% | -7.96% | |
| Form 10-Q Akero Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.98% | -7.96% | |
| Form 10-K Akero Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +3.35% | -3.71% | |
| Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update | Press release | -0.57% | +0.42% | |
| Form 10-Q Akero Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.57% | +0.42% |
Keep exploring
More AKRO: analyst actions → · SEC filings → · AKRO overview →